EPITOPE INC/OR/
8-K, 1997-05-29
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: CALIFORNIA MICRO DEVICES CORP, DEF 14A, 1997-05-29
Next: FRANKLIN TAX ADVANTAGED INTERNATIONAL BOND FUND, 497, 1997-05-29



                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                              --------------------


                                    FORM 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                Date of Report (Date of earliest event reported):

                                  May 27, 1997
                              --------------------


                                  EPITOPE, INC.
             (Exact name of registrant as specified in its charter)

                                     Oregon
                 (State or other jurisdiction of incorporation)

                                     1-10492
                              (Commission File No.)

                                   93-0779127
                        (IRS Employer Identification No.)


         8505 S.W. Creekside Place
              Beaverton, Oregon                                97008
   (Address of principal executive offices)                  (ZIP Code)


               Registrant's telephone number, including area code:

                                 (503) 641-6115



<PAGE>



Item 2.  Acquisition or Disposition of Assets.

         On May 27, 1997, Epitope,  Inc. ("Epitope" or the "Company")  completed
the rescission of its acquisition of Andrew and Williamson  Sales,  Co. ("A&W"),
pursuant  to  a  Settlement  Agreement  and  Release  dated  May  4,  1997  (the
"Settlement  Agreement").  As part of the  rescission,  the  520,000  shares  of
Epitope  common  stock  issued to acquire  A&W were  returned to the Company and
Company officers resigned their positions as directors and officers of A&W.

         The Company had  acquired A&W on December  12,  1996.  The  acquisition
involved  the merger of a Company  subsidiary  with and into A&W, as a result of
which the former  shareholders  of A&W  received  Epitope  common  stock and A&W
became a wholly owned subsidiary of the Company.

         In March 1997, an outbreak of Hepatitis A in Michigan occurred that was
allegedly   associated  with  frozen  strawberries  sold  by  A&W.  The  Company
subsequently  filed suit in the United States District Court for the District of
Oregon to rescind its  acquisition of A&W. On May 4, 1997,  the parties  entered
into the Settlement Agreement.

         In connection with the closing of the Settlement Agreement:

         (1)  The  520,000   shares  of  Epitope  common  stock  issued  in  the
acquisition of A&W were delivered to the Company for  cancellation.  The Company
also received A&W  nonvoting  preferred  stock with a liquidation  preference of
$5.7 million in return for the cancellation of loans by the Company to A&W.

         (2)  All  outstanding  A&W  common  stock  was  transferred  to Fred L.
Williamson,  Fred M. Williamson,  Keith Andrew,  and a trust established by Fred
Andrew.

         (3)  Company  officers  who were  also  directors  or  officers  of A&W
resigned their positions with A&W.

         (4) Fred L. Williamson, Fred M. Williamson, and Keith Andrew personally
guaranteed the $6.5 million credit facility  provided by A&W's bank lender.  The
facility is secured by A&W accounts  receivable  and  inventory.  The  Company's
guarantee of the facility will also continue in effect through November 1, 1998,
but the three individual guarantors have agreed to reimburse the Company for any
amounts it is required to pay under its guarantee.

         (5) A&W has  agreed to  indemnify  the  Company  for joint and  several
judgments against the two companies and for certain defense costs, to the extent
not reimbursed by insurance. The Company and A&W have each reserved the right to
assert claims  against the other in  connection  with suits in which only one is
named as a  defendant.  The  parties  have  otherwise  released  each other from
liabilities arising out of events occurring before the rescission.

         Additional  details of the  transaction  are  stated in the  Settlement
Agreement, which is an exhibit to this report.

Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits.

(a)      Financial statements of businesses acquired.

         None.


                                      - 1 -

<PAGE>




(b)      Pro forma financial information.

         None.

(c)      Exhibits.

         The exhibits to this report are listed in the exhibit  index  following
the signature page.





<PAGE>



                                   SIGNATURES


         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                  EPITOPE, INC.
                                  (Registrant)


                                  By    /s/ Gilbert N. Miller
                                        Gilbert N. Miller
                                        Executive Vice President and
                                        Chief Financial Officer

Dated:  May 28, 1997



<PAGE>


                                  EXHIBIT INDEX



2        Settlement  Agreement  and Release  dated as of May 4, 1997,  among the
         Company,  Keith R. Andrew and Kevin S. Andrew as  cotrustees  under the
         Fred W. and Virginia S. Andrew 1990  Revocable  Living Trust,  Keith R.
         Andrew individually, Fred L. Williamson, Fred M. Williamson, and Andrew
         and Williamson Sales, Co. (incorporated by reference to Exhibit 10.1 to
         the  registrant's  Quarterly  Report on Form 10-Q for the quarter ended
         March 31, 1997).




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission